Turning Russian science
into innovative drugs
Investments in biomedical innovations
Gurus BioPharm LLC (“Gurus”) is a research and investment company developing innovative drugs. We finance and develop groundbreaking Russian biopharmaceutical innovations from the early stages to commercialization at the global market. We provide an opportunity for accredited private investors to co-invest with us in cutting-edge innovations that can change current standards of healthcare in the world.
Projects for investment:
Innovative drugsAll projects...
Highly Effective cosmeticsAll projects...
Synergy of investment and research capabilities
Unlike traditional life sciences funds, Gurus conducts scientific research of original molecules. Therefore, we can enter the projects before the traditional venture funds, at the stage of scientific research. Projects with some incompleteness in technology development do not confuse us, if they have strong innovative potential. Gurus has expertise and technological capabilities to eliminate the shortcomings of the project and to unlock its potential.
Our technologies in drug development
Gurus has strong research competencies and platform technologies in drug development. Noxi Lab is a technological unit of Gurus which develops a research platform for generating innovative drugs, based on nitric oxide donors and pharmaceutical substance hybridization technology which uses biologically active linkers.
Joint investments in drug development
Gurus offers to accredited private investors to co-invest together with us in biopharmaceutical innovations. Traditional life sciences venture funds and pharmaceutical companies do not collaborate with private investors. Investing in innovative drugs is assumed to be one of the most profitable and fastest growing industries in the world and can be an interesting alternative to investing in shares of mature public companies.
Our project companies are Prostanit development, LLC, Noxi Lab, LLC
Gurus BioPharm LLC is a resident of Skolkovo Fund